Last reviewed · How we verify
Semaglutide Injectable Product
Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, reduce appetite, and promote weight loss.
Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, reduce appetite, and promote weight loss. Used for Type 2 diabetes mellitus, Chronic weight management in adults with obesity or overweight with weight-related comorbidities.
At a glance
| Generic name | Semaglutide Injectable Product |
|---|---|
| Also known as | semaglutide, Ozempic, Wegovy, Semaglutide plus lifestyle and cardiovascular risk factor management, Semaglutide and Lifestyle Counseling |
| Sponsor | Neurogastrx, Inc. |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes, Obesity |
| Phase | FDA-approved |
Mechanism of action
Semaglutide binds to and activates GLP-1 receptors on pancreatic beta cells, enhancing glucose-dependent insulin secretion and inhibiting glucagon release. It also acts on the central nervous system to reduce appetite and increase satiety, leading to decreased caloric intake and weight reduction. These combined effects improve glycemic control and body weight management in patients with type 2 diabetes and obesity.
Approved indications
- Type 2 diabetes mellitus
- Chronic weight management in adults with obesity or overweight with weight-related comorbidities
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
- Hypoglycemia
Key clinical trials
- Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss (PHASE2)
- Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes (PHASE4)
- Repurposing Semaglutide for the Treatment of Cocaine Use Disorder (PHASE2)
- Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3) (PHASE2)
- Effects of Semaglutide in HIV-Associated Lipohypertrophy (PHASE2)
- The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure (PHASE4)
- A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight (PHASE3)
- A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Semaglutide Injectable Product CI brief — competitive landscape report
- Semaglutide Injectable Product updates RSS · CI watch RSS
- Neurogastrx, Inc. portfolio CI